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Accumulation of amyloid- (A) peptides in the brain has been
suggested to be the primary event in sequential progression of
Alzheimer’s disease (AD). Here, we use Drosophila to examine
whether expression of either the human A40 or A42 peptide in
the Drosophila brain can induce pathological phenotypes resem-
bling AD. The expression of A42 led to the formation of diffused
amyloid deposits, age-dependent learning defects, and extensive
neurodegeneration. In contrast, expression of A40 caused only
age-dependent learning defects but did not lead to the formation
of amyloid deposits or neurodegeneration. These results strongly
suggest that accumulation of A42 in the brain is sufficient to
cause behavioral deficits and neurodegeneration. Moreover, Dro-
sophila may serve as a model for facilitating the understanding of
molecular mechanisms underlying A toxicity and the discovery of
novel therapeutic targets for AD.
A lzheimer’s disease (AD) is a neurodegenerative disordercharacterized clinically by progressive decline in memory
accompanied by histological changes, including neuronal loss
and the formation of neurofibrillary tangles (NFTs) and senile
plaques (1). The accumulation of amyloid- (A)42 peptide, the
major component of senile plaques, has been hypothesized to be
the primary event in AD pathogenesis (2, 3). The strongest
support for the A hypothesis comes from genetic analyses of
familial AD (FAD); most FAD mutations identified in A
precursor protein (APP), Presenilin1 (PS1) and Presenilin2
(PS2) genes appear to cause excessive accumulation of A42 (4).
Secretion of A peptides is a result of sequential cleavage of APP
by -secretase, a type I transmembrane glycosylated aspartyl
protease, and -secretase, a large protein complex that includes
at least four proteins, Presenilins (PS1 or PS2), Nicastrin, Aph-1,
and Pen-2 (for review, see ref. 5). The heterogeneity of -secre-
tase cleavage gives rise to a series of A peptides, including the
major species A40 and a smaller amount of A42.
To study AD pathogenesis in vivo, a number of AD mouse
models have been established and have successfully recapitu-
lated AD-like phenotypes, including abundant amyloid deposits,
astroglial activation, synaptic loss and dysfunction, behavioral
abnormalities, and neurodegeneration (6–15). In addition to
these mouse models, the model systems that allow high-
throughput genetic screening will facilitate the discovery of
genes involved in AD pathogenesis. Furthermore, one of the
intriguing issues that have not been elucidated in these trans-
genic mice is the pathological roles of each specific A species
(i.e., A40 andA42), because currently available mousemodels
mainly rely on overexpression of APP.
We use a Drosophila model (16) to compare the specific
pathological roles of A40 and A42. In Drosophila, all com-
ponents involved in the protein complex responsible for -secre-
tase activity are highly conserved (17), whereas -secretase
activity is absent or very low (18). An APP-like protein (APPL)
is also present in flies, although the A domain is not conserved.
A null mutation of APPL exhibits behavioral deficits, which are
rescued by a human APP transgene (19). Drosophila has been
used to study the physiological functions of APP and APPL in
synaptogenesis (20), axonal transport (21, 22), and apoptosis
(22). To determine whether Drosophila can be used as a model
to study the molecular basis of AD pathogenesis, we examined
the effects of A40 and A42 in the Drosophila brain using the
GAL4-UAS system (23). In particular, we were able to sepa-
rately analyze and determine specific roles for A40 and A42
in progressive learning defects and neurodegeneration.
Methods
Transgenic Flies. All A transgenic Drosophila strains were ob-
tained from Finelli et al. (ref. 16; see also ref. 24). For behavior
experiments, the elav-GAL4c155 line was outcrossed with w1118
(isoCJ1), an isogenic line, for five generations.
Western Blot and Mass Spectrometric Analysis. Fly heads were
homogenized in RIPA buffer (50 mM TrisHCl, pH 8.00.5%
sodium deoxycholate1% Triton X-100150 mMNaCl) contain-
ing 1% SDS, ultracentrifuged at 100,000  g for 1 h, and
supernatant was collected (SDS-soluble fraction). Protein ex-
tracts were immunoprecipitated with the 4G8 antibody (Signet
Laboratories, Dedham, MA), separated on 10–20% Tris-Tricine
gel (Invitrogen), and blotted with the 6E10 antiserum (Signet),
anti-A40 specific (Alpha Diagnostic, San Antonio, TX), or
anti-A42 specific (Oncogene Science) antibodies. SDS-
insoluble pellets were further homogenized in 70% formic acid
(Sigma) followed by ultracentrifugation at 100,000  g for 1 h,
and supernatant was collected [formic acid (FA) fraction]. FA
was evaporated by Speed Vac (Savant, SC100), and protein was
resuspended in dimethyl sulfoxiside (Sigma). The signal intensity
was quantified by using NIH IMAGE 1.6.2. Mass spectrometric
analysis was performed as described (25).
Pavlovian Olfactory Associative Learning. Olfactory associative
learning was performed as described (26). Briefly, f lies were
trained by exposure to electroshock paired with one odor
{octanol [103 (volvol)] or methylcyclohexanol [103 (vol
vol)]} for 60 s and subsequent exposure to a second odor without
electroshock for 60 s. Immediately after training, learning is
measured by allowing flies to choose between the two odors for
120 s. The performance index was calculated by subtracting the
number of flies making the incorrect choice from those making
the correct one, dividing by the total number of flies, and
multiplying by 100. Absolute odor avoidance and electric shock
reactivity were quantified as described (27).
Abbreviations: AD, Alzheimer’s disease; A, amyloid-; NFTs, neurofibrillary tangles; APP,
-amyloid precursor protein; FA, formic acid.
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Climbing Assay. Twenty flies were placed in a plastic vial and
gently tapped to the bottom. The number of flies at the top of
the vial was counted after 18 s of climbing under red light
(Kodak, GBX-2, Safelight Filter). The data shown represent
results from a cohort of flies tested serially for 40–60 days. The
experiment was repeated more than three times.
Survival Assay. Twenty to 30 flies were placed in a food vial. Each
vial was kept on its side at 25°C, 70% humidity, under a 12-h
light–dark cycle. Food vials were changed every 2–3 days, and
the dead flies were counted at that time. At least 100 flies were
prepared for each genotype, and the experiments were carried
out more than three times.
Anatomical Study. To detect neurodegeneration, fixed and per-
meabilized fly brains were stained with NBD C6-ceramide,
followed by counterstaining with propidium iodide (Molecular
Probes) (28). Samples were cleared by incubation in FocusClear
solution (PacGen, Vancouver) and viewed with a Zeiss LSM 510
confocal microscope with a 40 C-Apochromat water immer-
sion objective lens. To detect amyloid deposits, fixed and per-
meabilized brains were treated with 10% formic acid (Acros
Organics, Fairlawn, NJ), followed by immunostaining with a
mouse monoclonal anti-A antibody (Chemicon). ThioflavinS
staining was performed following Fay et al. (29). Transmission
electron microscope analysis was performed as described (30).
Results
Expression and Accumulation of A40 and A42 in Transgenic Fly
Brains. Each A40 or A42 peptide was fused to the rat pre-
proenkephalin signal peptide at the N terminus to ensure
secretion of A peptides once expressed (24). The A fusion
constructs have been shown to produce secreted A peptides
when expressed in human embryonic kidney cells (24) or in
Drosophila S2 cells (16). The A peptides were targeted to
express in all neurons in Drosophila by using the GAL4-UAS
system (23) (driven by the pan-neuronal elav-GAL4c155 driver;
see Methods). Several lines of evidence suggested that A40 or
A42 was produced appropriately in the fly brain. First, an A
signal of the correct size of 4 kDa was readily detected in
Western blots of flies that express either A40 or A42 but not
in controls (Fig. 1A Left, arrowhead). Putative oligomeric forms
of A peptides were also observed, including a 6-kDa band in
A40 flies (as better shown in Fig. 1B, asterisk), and 8- and
12-kDa bands in A42 flies (as better shown in Fig. 1C,
asterisks). Second, the A peptides were correctly cleaved from
the fused signal peptide, as indicated by the precise molecular
weight of A40 and A42 measured by mass spectrometry (Fig.
1D; Mr  4328.9004 for A40 and 4513.2754 Da for A42).
Third, the intactness of the C-terminal end of both A40 and
A42 was further confirmed by Western blotting with each
C-terminal end-specific antibody (Fig. 1B). Finally, the age-
dependent accumulation of A peptides showed biophysical
features similar to previous characterization (31–33), i.e., A40
was accumulated in the SDS-soluble fraction (Fig. 1C Upper
Right), whereas A42 accumulated in the SDS-insolubleFA-
soluble fraction (Fig. 1CLower Left). FromWestern blot analysis
of a 3-day-old head (Fig. 1A Left), we estimated that the
expression level of peptides (R  signal intensity compared to
A42males, n 3) was significantly higher for A40 (R 3.51
0.53 for males and R  1.42  0.40 for females) than for A42
(R 1.00 for males and R 0.19 0.04 for females), even after
taking into account the insoluble fraction (Fig. 1A Right, arrow-
head). The higher expression level of A peptides in male than
in female flies can be partly explained by the effect of gene
dosage compensation, because the GAL4 promoter is located on
the X chromosome.
Formation of Amyloid Deposits in A42 but Not in A40 Flies. To
determine whether expressed and accumulated A peptides
form A deposits in the fly brain, we performed whole-mount
immunohistochemical staining. In the neuropil region, 48-day-
old A42 fly brains showed the presence of abundant amyloid
deposits (Fig. 2B, arrowheads), and both the number and size of
the deposits were increased during aging (comparing Fig. 2A and
B, arrowheads). In contrast, such clear deposits were not ob-
served in A40 or control brains (Fig. 2 C and D). Importantly,
the staining signal observed in A40 brain (Fig. 2C, asterisk) is
not an A deposit but the expression of A40 in peduncle
structure, which is the axon bundle of mushroom body neurons
Fig. 1. Expression and accumulation profiling of A in transgenic fly heads.
(A) Expression levels of A peptides in SDS-soluble (Left) and FA fraction
(Right) at 3 days old. (B) Confirmation of the intactness of A40 or A42. 6E10
recognizes the common part of A40 and A42, whereas the 40 or 42 antibody
is specific to each C terminus. (C) Age-dependent accumulation of Apeptides
in SDS-soluble (Upper) and FA fraction (Lower). Arrowheads, monomeric A;
asterisks, putative oligomeric forms. (D) Mass spectrometric analysis of A
peptide from A40 (Upper) or A42 transgenic fly heads (Lower).
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(Kenyon cells). In the Kenyon cell body region, strong A
staining was observed in both A40 and A42 brains (Fig. 2
E–G) but not in control (Fig. 2H), confirming the specificity of
the antibody.
We also performed thioflavinS staining to label the A
deposits containing amyloid fibril structures. The thioflavinS-
positive deposits can be observed in the Kenyon cell body region
of A42 brains (Fig. 2I, arrows) but not in A40 or control brains
(Fig. 2 J and K, arrowheads). In contrast, no thioflavinS staining
was detected in the neuropil region (Fig. 2 L–N) even in A42
fly brains, which had abundant immunopositive A deposits as
shown above (comparing Fig. 2 B and L). We further analyzed
the A42 brains in both the Kenyon cell body and the neuropil
regions by transmission electron microscopy; however, there was
no evidence of clear amyloid fibril structure in both regions.
These results suggest that observed A42 deposits in our fly
brain are mainly diffused A deposits without clear amyloid
fibril core structures, although some of the deposits were stained
by thioflavinS. In summary, both A40 and -42 peptides accu-
mulated during aging (see Fig. 1C); however, only A42 peptides
could form diffused amyloid deposits in the fly brains.
Age-Dependent Olfactory Learning Defects Induced by A40 and
A42. Learning and memory of these flies were tested by using
a Pavlovian olfactory learning assay (26). For 2- to 3-day-old
adult f lies, no significant defect was observed in either A40 or
A42 flies (Fig. 3A). Both A40 and A42 flies began to show
a subtle but statistically significant learning defect at 6–7 days old
(Fig. 3B, asterisks). This decline became more obvious for 14- to
15-day-old flies (Fig. 3C, asterisks). The defect was greater in
male flies than in females, consistent with higher expression of
peptides in male flies (see Fig. 1A and text). Controls did not
show the sex difference at any time point (Fig. 3 A–C, compare
elavY and elav). For A40 flies, learning defects were
observed only in males but not in females (Fig. 3 A–C), suggest-
ing a much higher level of A40 than A42 is required to affect
learning ability (see Fig. 1A and text). We also examined odor
avoidance and electric-shock reactivity, two sensorimotor activ-
ities necessary for performing the learning task. There was no
significant difference among all groups for 14- to 15-day-old flies
for shock reactivity and avoidance of the odor methylcyclohexa-
nol (Fig. 3D). Avoidance of octanol is slightly lower in flies
expressing either A40 or A42 as compared to the UAS-
A42 and UAS-A40 controls but not significant com-
pared to the elav controls (Fig. 3D). This slight difference should
not contribute to observed learning defects, because A40
female flies showed a normal learning score (Fig. 3 A–C,
elav;;UAS-A40). That learning was normal in A40
female flies also suggests that progressive learning defects are a
result of A toxicity rather than of genetic background or stress
imposed by the expression of peptides.
Climbing Disability and Shortened Life Span in A42 but Not in A40
Flies. A42 flies started to show locomotor dysfunction after 3
weeks of age. The climbing ability of flies in response to light
Fig. 2. Detection of Adeposits in fly brain. (A–H) Whole-mount A immunostaining (green) and nuclear staining (red) in the neuropil region (A–D) and Kenyon
cell layer (E–H). Arrowheads, deposited A42 (A andB); asterisks, the peduncle structure, an axon bundle of Kenyon cells. (I–N) ThioflavinS staining in the Kenyon
cell (I–K) and neuropil regions (L–N). ThioflavinS-positive deposits were detected in A42 flies (I, arrows) but not in A40 or control (J and K, arrowheads). The
fiber structures seen in I–K are tracheas. Pd, peduncle; Kn, Kenyon cell layer; Ca, calyx; the dendritic structure of Kenyon cells. [Bar (D, H, and N)  50 m.]











tapping (34) began to decline significantly after 20 days in A42
flies but not in A40 flies (Figs. 4 A and E). The presence of
alterations in motor activity prevents us from examining learning
ability after 3 weeks. Even older A42 flies stayed at the bottom
of the vial and could not climb up the wall. Accompanying this
locomotor defect, the life span of A42 flies was also much
shorter, whereas A40 flies were not affected (Figs. 4 B and F).
To confirm the effect of A42, we examined another indepen-
dently isolated A42 line, which has a lower level of A42
expression (UAS-A42L). Similar results were obtained regard-
ing both climbing ability and life span (Fig. 4 C andD). We could
examine only females of this line, because both UAS-A42L and
elav-GAL4c155 transgenes are located on the X chromosome.
Late-Onset Progressive Neurodegeneration Caused by A42 but Not
by A40. Anatomical analysis by confocal microscope revealed
extensive neurodegeneration in aged A42 but not in A40 flies.
In 45-day-old A42 flies, we observed severe neuronal loss, as
indicated by the number of vacuoles in the Kenyon cell layer (Fig.
5D, arrowheads), a brain region crucial for olfactory learning
(35–37). Degeneration was also seen in other brain regions (Figs.
5 E and F). In contrast, age-matched A40 or control f lies did
not show obvious cell loss (Figs. 5 G and H). To eliminate the
possibility that observed neurodegeneration is a nonspecific
effect due to fly death, we analyzed 55-day-old A40 or control
f lies. We did not see much degeneration in either group of brains
(see Table 1, which is published as supporting information on the
PNAS web site). To determine the time of onset of degeneration,
we examined 3-, 14-, and 30-day-old A42 fly brains. There was
no detectable abnormality in 3- and 14- day-olds (Figs. 5 A and
B), whereas a small amount of cell loss started to appear in
30-day-old brains (Fig. 5C, arrowheads; see also Table 1). The
Fig. 3. Progressive loss of learning ability in A flies assayed by a Pavlovian
olfactory associative learning paradigm. (A–C) Learning abilities at 2–3 (A),
6–7 (B), and 14–15 days old (C) are presented in mean SEM. The numbers of
experiments are indicated on top of the bars. Asterisks show statistical differ-
ence from controls [(0.05, Tukey–Kramer honestly significant difference
(HSD)]. (D) No statistical difference in olfactory acuity and shock reactivity
between experimental genotype and appropriate control genotypes at 14–15
days old (n  8; except n  6 for octanol olfactory acuity for elavY;UAS-
A42 and shock reactivity for UAS-A40) at the level of   0.05
(Tukey–Kramer HSD).
Fig. 4. Progressive climbing disability and shortened life span in A42 flies.
(A, C, and E) Climbing ability in A42 flies (A and C, asterisks, P  0.001,
Student’s t test) and A40 flies (E). The SDs of 10 trials are within the symbols.
(B, D, and F) Survival rate of A42 flies (B and D) and A40 flies (F).
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average number and area of vacuoles are summarized in Table
1. Similar results were also observed when using a different Gal4
driver, OK107, which drives peptide expression preferentially in
the mushroom body structure (Fig. 5I, arrowheads; data not
shown). Cell death in the Kenyon cell layer of A42 flies was
analyzed in the ultrastructural level. The degenerating neurons
were readily identified, and vacuoles were detected as cell loss.
The majority of dying neurons showed the typical features of
necrotic-type cell death: digested cytoplasm (electron-lucent)
with swollen mitochondria (Fig. 5J, arrows), whereas nuclei were
relatively intact (Fig. 5J, indicated by N). Besides A depositions,
another characteristic lesion in AD patient brains is intracellu-
lary formed protein aggregates called NFTs. The major com-
ponent of NFTs is hyperphosphorylated  protein, which is
assembled into paired helical filament (PHF) structure (38–40).
The pathological interaction between A depositions and NFT
formation remains to be elucidated, because none of the AD
mouse models carrying abundant amyloid deposits developed
NFTs (6, 7, 9–12, 14, 15). Therefore, we were motivated to
determine whether accumulation of A42 leads to the formation
of NFT andor PHF structure with fly endogenous  protein
(41). PHF  was not detected by either immunoblotting or
electron microscopy in A42 fly head tissues.
Discussion
In this study, we have established accumulation of either A40
or A42 peptides in the Drosophila brain induces progressive
learning defects, but only A42 is capable of causing the
formation of diffused A deposits, locomotor dysfunction, neu-
rodegeneration, and premature death. It is remarkable to note
that in an organism with a life span of 2–3 months, accumulation
of A42 induces the sequential progression of pathological
symptoms resembling those in mouse ADmodels (6–15) and AD
patients (1, 42). Intriguingly, the onset of learning defects by
A42 occurs much earlier than that of degeneration in the flies,
similar to that observed in mouse AD models and AD patients
(7, 8, 43–46). Furthermore, that both A40 and A42 affect
learning but only A42 causes degeneration leads to the spec-
ulation that neuronal dysfunction and neurodegeneration may
be mediated by different mechanisms.
We have concluded that most amyloid deposits in A42 fly
brains are not cored (mature) plaques but diffused (immature)
deposits, because we could not detect clear amyloid fibrils at the
ultrastructural level. The lack of mature plaques may be due to
the short life span of A42 flies (within 50 days) andor the
absence of potential cofactors needed to form cored plaques in
the fly brain. On the other hand, this result indicates that the
cored plaque formation is not necessary to induce any of the
pathological phenotypes observed in the A42 flies.
A42 flies exhibit severe neurodegeneration in the absence of
cored plaques containing clear amyloid fibril structures and the
formation of NFTs. This has a parallel in studies that show
polyglutamine- (47) or -induced (48, 49) neurodegeneration can
be dissociated from the formation of nuclear inclusion or NFTs,
respectively. These facts support the notion that an ordered
prefibrillar oligomer, or protofibril, but not the fibrillar form,
may be responsible for cell death (50).
It has been reported that cognitive defects and A deposits
were not well correlated in AD patients (43, 46). In AD mouse
models, the development of synaptic dysfunction andor behav-
ioral deficits precedes the formation of amyloid deposits (13,
51, 52).
These facts are reminiscent of that A40 f lies showed
learning defects without amyloid deposits. As for the A42
f lies, we cannot conclude whether the deposits contribute to
behavioral defects, because the 3-day-old f lies already devel-
oped small amounts of deposits. Recently, soluble oligomeric
forms of A peptides have been suggested to be responsible for
synaptic dysfunctions (53). We detected putative oligomeric
forms of both A40 and A42 in the f ly brain (Fig. 1A),
whereas the pathological roles of these oligomers remain
elusive.
Conclusion
This study strongly supports the idea that excessive accumu-
lation of A42 is sufficient to cause memory defects and
neurodegeneration resembling AD and suggests that the mo-
lecular basis underlying A toxicity is conserved over different
organisms. Our A f lies may serve as a model for the genetic
and pharmacological screening system for AD therapeutics
targeting A-induced neurotoxicity and A clearance, as well
as for the understanding of the molecular and cellular basis of
AD pathogenesis.
Fig. 5. Late-onset progressive neurodegeneration in A42 brains. (A–H)
Progressive neuronal loss occurred in A42 (A–F, arrowheads) but not in A40
or control brains (G andH). (A–D,G, andH) The Kenyon cell region. (E) Medial
brain. (F) Lateral brain. Green, neuropil structure; red, nuclei. Arrows in D
indicate the aggregates, presumably amyloid deposits. Kn, Kenyon cell layer;
Ca, calyx; PB, protocerebral bridge; OL, optic lobe. [Bars (C and H)  50 m.]
(I) Neuronal loss induced by different Gal4 line, OK107. (Bar  50 m.) (J)
Ultrastructural analysis of degenerating neurons with digested cytoplasm
(electron-lucent) and swollen mitochondria (arrows). N, nucleus. (Bar 1m.)
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